Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea ; day:26 ; month:1 ; year:2021 ; pages:1-15
Rheumatology and therapy ; (26.1.2021), 1-15
- Creator
-
Ha, So-Young
Shim, Yoon-Bo
Lee, Min-Young
Koo, Bon-San
Kim, Jae-Hoon
Jeon, Ja-Young
Yoo, Hyun-Jeong
Kim, Young-Joo
Shin, Ju-Young
Park, Mi-Hai
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-021-00278-z
- URN
-
urn:nbn:de:101:1-2021031718572836081393
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ha, So-Young
- Shim, Yoon-Bo
- Lee, Min-Young
- Koo, Bon-San
- Kim, Jae-Hoon
- Jeon, Ja-Young
- Yoo, Hyun-Jeong
- Kim, Young-Joo
- Shin, Ju-Young
- Park, Mi-Hai
- SpringerLink (Online service)
Other Objects (12)
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug